停止帕克利塔塞尔前期治疗对救援药物使用的影响
Chang Yue Chui1, Bert N Storm2, Denise E Sampimon3
1Department of Clinical Pharmacy, Haga Teaching Hospital, Els Borst-Eilersplein 275, The Hague, The Netherlands. c.chui@hagaziekenhuis.nl.
Cancer chemotherapy and pharmacology
|January 6, 2026
概括
在服用两剂帕克利塔塞尔后停止常规前期治疗,增加了对过敏反应 (HSR) 的救援药物的使用. 虽然反应是可以管理的,但需要进一步的研究来确认所有患者的安全性.
科学领域:
- 在瘤学瘤学.
- 临床药房 临床药房
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕克利塔塞尔诱导的过敏反应 (HSR) 在初始治疗期间很常见.
- 目前的方案包括用克莱马斯丁和德克萨米他进行预治疗,以减轻HSRs.
- 减少前期治疗可以减少不良影响和医疗保健成本.
研究的目的:
- 为了评估在两次无HSR的帕克利塔克塞尔管理后停止前期治疗的影响.
- 为了确定在协议更改后,救援药物的使用是否显著增加.
- 评估减少前期药物治疗策略的安全性和有效性.
主要方法:
- 追溯性,观察性,非劣等性研究设计.
- 连续接受前期药物治疗的患者与在两剂后停止治疗的患者的比较.
- 主要结局:在HSR中使用救援药物的发生率.
主要成果:
- 由于缺乏足够的统计能力,没有证明非劣等性.
- 与持续前期治疗组 (4.1%) 相比,在停止前期治疗组 (10.8%) 中,救援药物的使用率更高.
- 观察到的救援药物使用量的增加没有达到统计学意义,反应很温和.
结论:
- 在服用两剂帕克利塔塞尔后停止前期治疗导致救援药物使用的发病率更高.
- 过敏反应通常是轻微和可控的,允许大多数患者完成治疗.
- 需要进行进一步的研究,以制定最终的安全指南,以缓解帕克利塔塞尔前期治疗的升级.
相关概念视频
Cardiopulmonary Resuscitation IV: Pharmacological Management
639
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
639
Desensitization and Tachyphylaxis
3.0K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
594
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
594
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
227
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
227

